Their primary goal is securing the necessary funding to propel the testing of our lead compound, volasertib, in five types of pediatric cancer (Ewing’s sarcoma, alveolar rhabdomyosarcoma, medullobla...
Leer másOncoheroes Biosciences is now at a crucial moment in its quest to find effective therapies for pediatric cancer patients, as they have the unprecedented opportunity to test Volasertib, one of its thre...
Leer másOncoheroes Biosciences, una biotecnológica centrada en el avance de nuevas terapias contra el cáncer infantil, ha anunciado hoy que la Administración de Alimentos y Medicamentos de EE.UU. ha conced...
Leer másOncoheroes Biosciences, Inc. ("Oncoheroes") ha anunciado hoy que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) ha permitido a la biotecnológica con sede en Boston segu...
Leer másFoundation for Addie’s Research Joins Oncoheroes moving volasertib into a clinical trial to create more and better options for children fighting cancer.
Leer másVall d’Hebron Research Institute (VHIR), a world-leading healthcare institution where healthcare, research, innovation and education go hand in hand, and Oncoheroes Biosciences, a biotech company ex...
Leer másOncoheroeOncoheroes Biosciences, Inc. (“Oncoheroes”), and Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”) have signed a worldwide, exclusive pediatric licensing agreement for dovitinib...
Leer másIn April 2021, Rally Foundation For Childhood Cancer Research invested for the first time in Oncoheroes Biosciences. Today, we are thrilled to announce that Rally Foundation is investing again based o...
Leer másVenture philanthropy is a growing trend across many important social issues.
Leer másIn October 2019, The Andrew McDonough B+ Foundation invested for the first time in Oncoheroes Biosciences, a biotech company advancing new therapies for childhood cancer.
Leer másPediatric oncologists are forced to adjust adult cancer treatments for childhood cancer due to insufficient specific therapies for children with cancer.
Leer másChildhood cancer is considered a rare disease that accounts for about 1% of all U.S. cancer diagnoses. Because of improved tumor detection and treatment advances in recent decades, 84% of children ...
Leer más